<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00677248</url>
  </required_header>
  <id_info>
    <org_study_id>2007-007831-24</org_study_id>
    <nct_id>NCT00677248</nct_id>
  </id_info>
  <brief_title>LDL-Cholesterol Lowering Effect of KB2115 as Add on to Ezetimibe</brief_title>
  <official_title>A Phase II, Placebo-Controlled, Double-Blind, Randomised, 10-Week, Parallel-Group Study to Assess the Efficacy of Different Doses of KB2115 as Add on to Ezetimibe Treatment in Patients With Primary Hypercholesterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karo Bio AB</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karo Bio AB</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Eprotirome (KB2115) is a liver selective thyroid hormone that can induce hyperthyroidism in
      the liver, while an euthyroid state is preserved in the extrahepatic tissue. Eprotirome has
      in clinical trials demonstrated pronounced reduction of several independent risk factors for
      the development of atherosclerotic cardiovascular diseases.

      The purpose of the study is to assess the efficacy and safety of KB2115 as add on therapy to
      ezetimibe following 10 weeks of exposure compared to placebo. The aim of the study is to
      assess efficacy (LDL-cholesterol lowering effects) and safety of KB2115 and to define a
      clinically relevant dose or dose range for future studies.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">September 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Triglycerides</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Ezetimibe and placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eprotirome dose 1 and ezetimibe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eprotirome dose 2 and ezetimibe</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eprotirome dose 3 and ezetimibe</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ezetimibe and placebo</intervention_name>
    <description>Placebo or three different doses of eprotirome added to ezetimibe treatment</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eprotirome and ezetimibe</intervention_name>
    <description>Placebo or three different doses of eprotirome added to ezetimibe treatment</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females aged 18 to 75 years

          -  Patient with primary hypercholesterolemia with an LDL-cholesterol &gt; 3.0 mmol/L

          -  At randomization, diet as instructed by the investigator during the last 4 weeks prior
             to randomization and willingness to follow these instructions throughout the study

        Exclusion Criteria:

          -  History of somatic or psychiatric disease/condition, which may interfere with the
             objectives of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jens D Kristensen, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Karo Bio AB</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karo Bio AB</name>
      <address>
        <city>HUddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>May 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 12, 2008</study_first_submitted>
  <study_first_submitted_qc>May 13, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2008</study_first_posted>
  <last_update_submitted>November 27, 2008</last_update_submitted>
  <last_update_submitted_qc>November 27, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 1, 2008</last_update_posted>
  <responsible_party>
    <name_title>Chief Medical Officer</name_title>
    <organization>Karo Bio AB</organization>
  </responsible_party>
  <keyword>Eprotirome</keyword>
  <keyword>KB2115</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>hypercholesterolemia</keyword>
  <keyword>hypertriglyceridemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

